πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

131 results for β€œNew” Clear

  1. Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial
  2. The clinical trial to study a new drug, AP-2.

    Lacuna Pharma Pty Ltd

    ALS and related disorders like frontotemporal dementia and Alexander disease.

    phase 1 other active

    1 trial
  3. new formulations of 611

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Atopic Dermatitis

    phase 1 small molecule active

    1 trial
  4. β€žINSIGHTβ€œ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial
  5. Terrosa 20 micrograms/80 microliters solution for injection in pre-filled pen, Acido Alendronico Aurobindo 70 mg compresse

    Gedeon Richter Australia Pty Ltd

    Prevention of new morphometric vertebral fractures and/or worsening of previous vertebral fractures.

    approved small molecule active

    1 trial
  6. a control group

    The First People's Hospital of Lianyungang

    Disorder of Stomach Function and Feeding Problems in Newborn

    approved small molecule completed

    1 trial
  7. CMOP+Chidamide

    The First People's Hospital of Lianyungang

    Newly Diagnosed Peripheral T-cell Lymphoma

    small molecule active

    1 trial
  8. New Infant Cereal

    Quantum Biopharma

    Infant Nutrition Sciences

    other completed

    1 trial
  9. New infant formula

    United Therapeutics Europe Ltd

    Functional Gastrointestinal Disorders

    other active

    1 trial
  10. new extensively hydrolysed formula

    United Therapeutics Europe Ltd

    Protein Allergy

    other completed

    1 trial
  11. new infant formula

    United Therapeutics Europe Ltd

    Functional Constipation

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources